Literature DB >> 24268690

Comparative functional characterization of canine IgG subclasses.

Lisa M Bergeron1, Erin E McCandless2, Steve Dunham2, Bill Dunkle2, Yaqi Zhu2, John Shelly2, Sandra Lightle2, Andrea Gonzales2, Graeme Bainbridge2.   

Abstract

To date, very little is known about the functional characteristics of the four published canine IgG subclasses. It is not clear how each subclass engages the immune system via complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC), or how long each antibody may last in serum. Such information is critical for understanding canine immunology and for the discovery of canine therapeutic monoclonal antibodies. Through both in vitro and ex vivo experiments to evaluate canine Fc's for effector function, complement binding, FcRn binding, and ADCC, we are now able to categorize canine subclasses by function. The subclasses share functional properties with the four human IgG subclasses and are reported herein with their function-based human analog. Canine Fc fusions, canine chimeras, and caninized antibodies were characterized. Canine subclasses A and D appear effector-function negative while subclasses B and C bind canine Fc gamma receptors and are positive for ADCC. All canine subclasses bind the neonatal Fc receptor except subclass C. By understanding canine IgGs in this way, we can apply what is known of human immunology toward translational and veterinary medicine. Thus, this body of work lays the foundation for evaluating canine IgG subclasses for therapeutic antibody development and builds upon the fundamental scholarship of canine immunology.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADCC; CDC; CDR; Canine; Effector functions; Fc receptor; IgG subclass; Immunoglobulin; antibody-dependent cell-mediated cytotoxicity; cell-mediated cytotoxicity; complementarity determining region

Mesh:

Substances:

Year:  2013        PMID: 24268690     DOI: 10.1016/j.vetimm.2013.10.018

Source DB:  PubMed          Journal:  Vet Immunol Immunopathol        ISSN: 0165-2427            Impact factor:   2.046


  32 in total

1.  A canine-derived chimeric antibody with high neutralizing activity against canine parvovirus-2.

Authors:  Lixuan Zhou; Hongchao Wu; Mengmeng Du; Huanhuan Song; Ningning Huo; Xiao Chen; Xiaorui Su; Weiguo Li; Lulu Wang; Jie Wang; Baicheng Huang; Feifei Tan; Kegong Tian
Journal:  AMB Express       Date:  2022-06-15       Impact factor: 4.126

2.  Immune protection against Trypanosoma cruzi induced by TcVac4 in a canine model.

Authors:  José E Aparicio-Burgos; José A Zepeda-Escobar; Roberto Montes de Oca-Jimenez; José G Estrada-Franco; Alberto Barbabosa-Pliego; Laucel Ochoa-García; Ricardo Alejandre-Aguilar; Nancy Rivas; Giovanna Peñuelas-Rivas; Margarita Val-Arreola; Shivali Gupta; Felix Salazar-García; Nisha J Garg; Juan C Vázquez-Chagoyán
Journal:  PLoS Negl Trop Dis       Date:  2015-04-08

3.  IgG1 as a potential biomarker of post-chemotherapeutic relapse in visceral leishmaniasis, and adaptation to a rapid diagnostic test.

Authors:  Tapan Bhattacharyya; Armon Ayandeh; Andrew K Falconar; Shyam Sundar; Sayda El-Safi; Marissa A Gripenberg; Duncan E Bowes; Caroline Thunissen; Om Prakash Singh; Rajiv Kumar; Osman Ahmed; Osama Eisa; Alfarazdeg Saad; Sara Silva Pereira; Marleen Boelaert; Pascal Mertens; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2014-10-23

Review 4.  Cats are not small dogs: is there an immunological explanation for why cats are less affected by arthropod-borne disease than dogs?

Authors:  Michael J Day
Journal:  Parasit Vectors       Date:  2016-09-20       Impact factor: 3.876

Review 5.  Canine cancer immunotherapy studies: linking mouse and human.

Authors:  Jiwon S Park; Sita S Withers; Jaime F Modiano; Michael S Kent; Mingyi Chen; Jesus I Luna; William T N Culp; Ellen E Sparger; Robert B Rebhun; Arta M Monjazeb; William J Murphy; Robert J Canter
Journal:  J Immunother Cancer       Date:  2016-12-20       Impact factor: 13.751

6.  A canine chimeric monoclonal antibody targeting PD-L1 and its clinical efficacy in canine oral malignant melanoma or undifferentiated sarcoma.

Authors:  Naoya Maekawa; Satoru Konnai; Satoshi Takagi; Yumiko Kagawa; Tomohiro Okagawa; Asami Nishimori; Ryoyo Ikebuchi; Yusuke Izumi; Tatsuya Deguchi; Chie Nakajima; Yukinari Kato; Keiichi Yamamoto; Hidetoshi Uemura; Yasuhiko Suzuki; Shiro Murata; Kazuhiko Ohashi
Journal:  Sci Rep       Date:  2017-08-21       Impact factor: 4.379

Review 7.  Strengths and Weaknesses of Pre-Clinical Models for Human Melanoma Treatment: Dawn of Dogs' Revolution for Immunotherapy.

Authors:  Giuseppina Barutello; Valeria Rolih; Maddalena Arigoni; Lidia Tarone; Laura Conti; Elena Quaglino; Paolo Buracco; Federica Cavallo; Federica Riccardo
Journal:  Int J Mol Sci       Date:  2018-03-10       Impact factor: 5.923

8.  Emergent canine visceral leishmaniasis in Argentina: Comparative diagnostics and relevance to proliferation of human disease.

Authors:  Kyoko Fujisawa; Charlotte Silcott-Niles; Poppy Simonson; Daniela Lamattina; Cristian A Humeres; Tapan Bhattacharyya; Pascal Mertens; Caroline Thunissen; Victoria O'Rourke; Magdalena Pańczuk; James A Whitworth; Oscar Daniel Salomón; Michael A Miles
Journal:  PLoS Negl Trop Dis       Date:  2021-07-19

9.  Use of a recombinant cysteine proteinase from Leishmania (Leishmania) infantum chagasi for the Immunotherapy of canine visceral Leishmaniasis.

Authors:  Josie Haydée Lima Ferreira; Lucilene Dos Santos Silva; Ieda Maria Longo-Maugéri; Simone Katz; Clara Lúcia Barbiéri
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

Review 10.  Immunotherapy for Dogs: Running Behind Humans.

Authors:  Hans Klingemann
Journal:  Front Immunol       Date:  2018-02-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.